ZOMETA IN COMPLEX TREATMENT FOR GENERALIZED BREAST CANCER: A CLINICAL CASE
https://doi.org/10.17650/1994-4098-2009-0-1-2-41-43
Abstract
The paper describes a case of generalized breast cancer treated with Zometa in combination with chemotherapy. It shows it necessary to supplement chemotherapy with zoledronate in case of bone changes in order to improve the results the antitumor treatment performed.
About the Author
L. V. Bolotina
P.A. Herzen Moscow Research Institute of Oncology
Russian Federation
Russian Federation
References
1. Coleman R.E. Skeletal complications of malignancy. Cancer 1997;80:1588—94.
2. Lipton A. Theriault R.L., Hortobaggyi G.N. et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Long term follow-up of two randomized, placebo-controlled tri- als. Cancer 2000;88:1082—90.
3. Kanis J.A., McCloskey E.V. Bone turnover and biochemical markers in malignancy. Cancer 1997;80(8):1691—5.
4. Fleisch H. Bisphosphonates in bone disease — from the laboratory to the patient. New York: The Parthenon Publishing Group, 1997.
5. Mundy G.R. Preclinical studies of metastases: experimental models and novel techniques to detect micrometastases. In: Program and abstracts of 22nd San Antonio Breast Cancer Symposium; 1999.
6. Senaratne W.G., Pirianov G., Mansi J.L. et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000;82:1459—68.
7. Hiraga T., Williams P.J., Ueda A. et al. Zoledronic acid inhibits visceral metas- tases in the 4T1/luc mouse breast cancer model. Clin Cancer Res ;10:4559—67.
Review
For citations:
Bolotina L.V. ZOMETA IN COMPLEX TREATMENT FOR GENERALIZED BREAST CANCER: A CLINICAL CASE. Tumors of female reproductive system. 2009;(1-2):41-43. (In Russ.) https://doi.org/10.17650/1994-4098-2009-0-1-2-41-43
Views:
534
Email this article 